At the time of writing, the past few weeks have been busy, but also a time of reflection for me. As the Director of the Centre for Biomedicine and Society (CBAS), Kings College London, we have been sending out invitations to our official launch, to be held in June 2009. As part of the launch, the three CBAS Professors, Steve Wainwright, Brian Salter and myself, are giving inaugural lectures. Therefore many of the invitations have gone out to individuals who have supported us in our careers, and who have helped us set up our Centre. The enthusiastic replies I've received have made me reflect back over the past 15 years to when I began my MSc, and think about the number of people who have helped me on my way. I have been amazed and delighted at the distances people are prepared to travel to be there on the day and help us celebrate our launch.
Preparing for the launch has also made me reflect on the path my academic career has taken. My PhD focused on how teenagers with asthma and diabetes manage their chronic illness, but in 1999 my first post-doctoral post shifted me into the area of the sociology of ethics, where I have remained. I have developed a particular interest in the clinical, ethical and social issues around innovative health technologies, and consider myself extremely fortunate that my developing interest coincided with the launch of the Wellcome Trust Biomedical Ethics Programme, which has funded much of my research. Projects have focused on such morally contested areas as the status of the fetus, preimplantation genetic diagnosis, prenatal screening, human embryonic stem cell (hESC) research and embryo donation for research purposes. It has been a privilege to come into contact with all those who work in or are involved in these areas, and who have helped change my thinking so profoundly.
Over the past 10 years I have worked with some exceptional colleagues from various disciplines, and we were recently awarded a five-year Wellcome Trust Strategic Award, to enable us to develop the London & Brighton Translational Ethics Centre (LABTEC). Our research programme aims to expand the work of our interdisciplinary team, through building capacity and adding value in three interlinking domains: providing research training and academic career development; developing innovative methodological approaches combining normative and empirical ethics; and undertaking substantive empirical and theoretical work on the ethics of translational research. The UK has one of the most tightly regulated but liberal frameworks for hESC research, with the government strongly promoting it as a global centre for translational research. However, the variety of sources of stem cells and the patient-driven urgency for treatments have created numerous ethical issues in this rapidly developing field. Our LABTEC research programme focuses on key developments in hESC research and neuroscience as critical instances of the translational interface between research and treatment and science and medicine, including the use of inter-species embryos; boundaries/overlaps between experimental research and treatment; and non-human primate research for neurological treatments. The central ethical question is the acceptability of changing what it means to be human and/or a person, but others include the impact on human/animal rights and dignity; the interests of future generations; the interpretation of safety and risk; the relationship between personal beliefs and professional demands and responsibilities; the place of values in patient choice; and the shifts in moral landscapes as research progresses.
We have a particular interest in the practitioners and scientists who work at the key interface of the translational process, namely research ethics and experimental treatment ethics, and we will be exploring how these might mutually influence each other. For example, are the ethics of working with inter-species embryos shaped by the sorts of demands placed on clinicians in terms of their duty of care to patients, including patient demand for treatment 'at any cost'? Do the ethics of working with inter-species embryos influence the ethics of clinician-researchers, and their willingness to take risks? How do moral landscapes shift as research progresses? The ethical 'integrity' of this work is, of course, crucially important to both those directly involved in the field, including scientists, clinicians, and patients, and to those of us indirectly involved.
Most of the LABTEC co-applicants will also be participating in our CBAS launch and, in many ways, I see it as the launch of LABTEC too -so it is a double celebration. For example, my friend and colleague Bobbie Farsides, co-applicant and Editor of Clinical Ethics, will be introducing our plenary speaker, Professor Renée C Fox, Annenberg Professor Emerita of the Social Sciences, University of Pennsylvania. I am thrilled that Renée has agreed to give our Keynote Plenary: she was a key pioneer in the sociology of bioethics, and her work has greatly influenced and inspired all of us who have attempted to follow in her footsteps. She has also recently joined the Editorial Advisory Board of Clinical Ethics where she is already making her mark, particularly by encouraging more junior researchers. As I said earlier, one of our key LABTEC aims is to build capacity by providing research training and academic career development, thereby passing on skills to a new generation of researchers, and expanding the critical mass of multi/ interdisciplinary expertise available to undertake such work. I hope, as I reflect on our launch, that the event will be a formal recognition of this aim.
